[Platelet aggregation and antiplatelet agents in acute coronary syndromes].
Antiplatelet agents are the cornerstone therapy of acute coronary syndromes. In the setting of ST elevation myocardial infarction, antiplatelet therapy prevent the prothrombotic effect of reperfusion therapy including thrombolysis and primary percutaneous coronary intervention. In non ST-elevation acute coronary syndromes, antiplatelet therapy prevent s complete coronary thrombotic occlusion and therefore the occurrence of ST elevation myocardial infarction. Antiplatelet agent benefit is related to the patient's risk profile. It is well established that combined antiplatelet therapy is the most effective in high risk patients. Several important issues have to be faced including the identification of non responders, dose adjustment and the management of temporary interruption of antiplatelet agents in stable coronary artery disease patients.
Collet
Jean-Philippe
JP
Institut de cardiologie, Hôpital de la Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France. jean-philippe.collet@psl.ap-hop-paris.fr
Choussat
Rémi
R
Montalescot
Gilles
G
D000208:Acute Disease; D003324:Coronary Artery Disease / Q000150:complications; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D015425:Myocardial Reperfusion; D018579:Patient Selection; D010974:Platelet Aggregation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D015912:Thrombolytic Therapy
D010975:Platelet Aggregation Inhibitors